CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CLD HEALTH OUTCOMES
CIRRHOSIS
CIRRHOSIS HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty CLDF Committees 2023 GI Fellow Board of Advisors
Embassy of Education
Slide Library Publications Webcasts Abstract Library
 
PBC Disease Content  
Publications
 
Slide Library
   Released: 2022
test
PBC: Diagnosis and Current Management Strategies
41 slides
 
 
   Released: 2020
test
Clinical Insights Into the Management of Primary Biliary Cholangitis (PBC)
53 slides
 
 
   Released: 2020
test
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current and Emerging Treatments
48 slides
 
 
 
Recorded Educational Webinar

Webcast Library
     
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current and Emerging Treatments   CME Webcast
CME eNewsletter
     
  Newsletter  
     
  Credit Designation  
  1.0 AMA PRA  
  Category 1 Credit(s)™  
  View  
  Provided by:
CLDF

Accredited by:
CLDF

This educational material was supported by an educational grant Intercept Pharmaceuticals. 		 
     
 
 
Primary Biliary Cholangitis: Diagnosis and Management
 
Target Audience
The target audience for this enduring activity is hepatologists, gastroenterologists, advanced practice registered nurses, and physician assistants who manage patients with PBC.
 
Educational Objectives
Upon completion of this activity, participants should be better able to:
• Describe evolving patient management strategies for primary biliary cholangitis (PBC)
• Discuss the latest treatment algorithms for PBC and apply them to clinical practice
 
Accreditation Statement
Please see page 1 of the newsletter for full accreditation statement.
 
 
 
 
Abstract Library
1.Autoimmune liver diseases and diabetes
 

Eur J Gastroenterol Hepatol. 2023 Sep 1;35(9):938-947. doi: 10.1097/MEG.0000000000002594.Epub 2023 Jun 22.

 

Anne-Sofie H Jensen 1 2, Henriette Ytting 2 3 4, Marie Winther-Sørensen 1, Johan Burisch 2, Annika Bergquist 2 5, Lise Lotte Gluud 2 4, Nicolai J Wewer Albrechtsen 1 6
 
2.Risk Stratification in Primary Biliary Cholangitis
 

J Clin Med. 2023 Sep 1;12(17):5713. doi: 10.3390/jcm12175713.

Francesco Martini 1, Daniele Balducci 1, Martina Mancinelli 1, Valerio Buzzanca 1, Elena Fracchia 1, Giuseppe Tarantino 1, Antonio Benedetti 1, Marco Marzioni 1, Luca Maroni 1

 
 
3.Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
 

Hepatology. 2023 Aug 1;78(2):397-415. doi: 10.1097/HEP.0000000000000395.Epub 2023 Apr 6.

 

Gideon M Hirschfield 1, Mitchell L Shiffman 2 3, Aliya Gulamhusein 4, Kris V Kowdley 5, John M Vierling 6, Cynthia Levy 7, Andreas E Kremer 8, Ehud Zigmond 9, Pietro Andreone 10 11, Stuart C Gordon 12, Christopher L Bowlus 13, Eric J Lawitz 14, Richard J Aspinall 15, Daniel S Pratt 16, Karina Raikhelson 17 18, Maria S Gonzalez-Huezo 19, Michael A Heneghan 20, Sook-Hyang Jeong 21, Alma L Ladrón de Guevara 22, Marlyn J Mayo 23, George N Dalekos 24, Joost P H Drenth 25, Ewa Janczewska 26 27, Barbara A Leggett 28, Frederik Nevens 29 30, Victor Vargas 31 32, Eli Zuckerman 33, Christophe Corpechot 34, Eduardo Fassio 35, Holger Hinrichsen 36, Pietro Invernizzi 37 38, Palak J Trivedi 39 40 41 42, Lisa Forman 43, David E J Jones 44, Stephen D Ryder 45, Mark G Swain 46, Alexandra Steinberg 47, Pol F Boudes 47, Yun-Jung Choi 47, Charles A McWherter 47; ENHANCE Study Group*

Collaborators

  • ENHANCE Study Group*: 

Raul Adrover, Saurabh Agrawal, Elmar Aigner, Agustin A Martinez, Abu-Mouch S Alden, Raul Jesús Andrade Bellido, Marco Antonio Arrese Jiménez, Walid Ayoub, Seth J Baum, Ziv Ben-Ari, Marina Berenguer, Christoph Berg, Fernando O Bessone, Alan Bonder, Brian B Borg, Carlos Gustavo Bresky Ruiz, Peter Buggisch, Jose Luis Calleja Panero, Elizabeth J Carey, Michal Carmiel-Haggai, Francesca Carubbi, Pilar Castillo Grau, Chin L Ch'ng, Nicoleta-Claudia Cimpoeru, Raúl C Omaña, Lynsey Corless, Charlotte Costentin, Marc Deschênes, Yvonne Dörffel, Predrag Dugalic, Geoffrey C Farrell, José L Fernández, Annarosa Floreani, Sven Francque, Bradley L Freilich, Francisco Alejandro Fuster Saldias, Michael R Galambos, Joseph Galati, Andrea Galli, Nathalie Ganne-Carrie, Natalia Geyvandova, Liliana-Simona Gheorghe, Richard Gilroy, Aparna Goel, Tobias Goeser, Susan Greenbloom, Waldemar Halota, Stephen A Harrison, Marek Hartleb, Jeong Heo, Harald Hofer, Gábor Horváth, Jonathan C Huang, Jason L Huffman, Béla Hunyady, Steven Johnson, Yiannis Kallis, Arun Khazanchi,
 
4.Risk of fractures and postfracture mortality in 3980 people with primary biliary cholangitis: A population-based cohort study
 

J Intern Med. 2023 Aug;294(2):164-177. doi: 10.1111/joim.13624. Epub 2023 Mar 5.

 

Johanna Schönau 1, Axel Wester 2, Jörn M Schattenberg 1, Hannes Hagström 2 3
 
5.Hematologic traits and primary biliary cholangitis: a Mendelian randomization study
 

J Hum Genet. 2023 Aug;68(8):559-563. doi: 10.1038/s10038-023-01146-0. Epub 2023 Apr 3.

 

Bin Ke 1, Chunyu Li 2, Huifang Shang 3
 
6.D-Penicillamine-Induced Myasthenia Gravis-A Probable Complication of Wilson's Disease Treatment-A Case Report and Systematic Review of the Literature
 

Life (Basel). 2023 Aug 10;13(8):1715. doi: 10.3390/life13081715.

 

Agnieszka Antos 1, Anna Czlonkowska 1, Jan Bembenek 2, Iwona Kurkowska-Jastrzebska 1, Tomasz Litwin 1
 
7.Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis
 

JHEP Rep. 2023 Apr 29;5(8):100782. doi: 10.1016/j.jhepr.2023.100782. eCollection 2023 Aug.

 

Richard J Thompson 1, Reha Artan 2, Ulrich Baumann 3, Pier Luigi Calvo 4, Piotr Czubkowski 5, Buket Dalgic 6, Lorenzo D'Antiga 7, Angelo Di Giorgio 7, Özlem Durmaz 8, Emmanuel Gonzalès 9, Tassos Grammatikopoulos 1 10, Girish Gupte 11, Winita Hardikar 12, Roderick H J Houwen 13, Binita M Kamath 14, Saul J Karpen 15, Florence Lacaille 16, Alain Lachaux 17, Elke Lainka 18, Kathleen M Loomes 19, Cara L Mack 20, Jan P Mattsson 21, Patrick McKiernan 11, Quanhong Ni 21, Hasan Özen 22, Sanjay R Rajwal 23, Bertrand Roquelaure 24, Eyal Shteyer 25, Etienne Sokal 26, Ronald J Sokol 27, Nisreen Soufi 28, Ekkehard Sturm 29, Mary Elizabeth Tessier 30, Wendy L van der Woerd 13, Henkjan J Verkade 31, Jennifer M Vittorio 32, Terese Wallefors 21, Natalie Warholic 21, Qifeng Yu 21, Patrick Horn 21, Lise Kjems 21
 
8.Emerging Therapeutic Strategies in The Fight Against Primary Biliary Cholangitis
 

J Clin Transl Hepatol. 2023 Aug 28;11(4):949-957. doi: 10.14218/JCTH.2022.00398.Epub 2023 Mar 16.

 

Abigail Medford 1, Jonathan Childs 1, Ashleigh Little 1, Sanjukta Chakraborty 1, Leonardo Baiocchi 2, Gianfranco Alpini 3, Shannon Glaser 1
 
9.Adequate vs. deep response to UDCA in PBC: To what extent and under what conditions is normal ALP level associated with complication-free survival gain?
 

Hepatology. 2023 Jul 3. doi: 10.1097/HEP.0000000000000529. Online ahead of print.

 

Christophe Corpechot 1, Sara Lemoinne 1, Pierre-Antoine Soret 1, Bettina Hansen 2 3, Gideon Hirschfield 3, Aliya Gulamhusein 3, Aldo J Montano-Loza 4, Ellina Lytvyak 5, Albert Pares 6, Ignasi Olivas 6, John E Eaton 7, Karim T Osman 7, Christoph Schramm 8, Marcial Sebode 8, Ansgar W Lohse 8, George Dalekos 9, Nikolaos Gatselis 9, Frederik Nevens 10, Nora Cazzagon 11, Alessandra Zago 11, Francesco Paolo Russo 11, Annarosa Floreani 11, Nadir Abbas 12, Palak Trivedi 13, Douglas Thorburn 14, Francesca Saffioti 14, Laszlo Barkai 14, Davide Roccarina 14, Vicenza Calvaruso 15, Anna Fichera 15, Adèle Delamarre 16, Natalia Sobenko 17, Alejandra Maria Villamil 17, Esli Medina-Morales 18, Alan Bonder 18, Vilas Patwardhan 18, Cristina Rigamonti 19, Marco Carbone 20, Pietro Invernizzi 20, Laura Cristoferi 20, Adriaan van der Meer 21, Rozanne de Veer 21, Ehud Zigmond 22, Eyal Yehezkel 22, Andreas E Kremer 23, Ansgar Deibel 23, Tony Bruns 24, Karsten Große 24, Aaron Wetten 25, Jessica Katharine Dyson 25, David Jones 25, Jérôme Dumortier 26, Georges-Philippe Pageaux 27, Victor de Lédinghen 16, Olivier Chazouillères 1, Fabrice Carrat 28; Global & ERN Rare-Liver PBC Study Groups
 
10.Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis
 

Am J Gastroenterol. 2023 Jul 1;118(7):1196-1203. doi: 10.14309/ajg.0000000000002128.Epub 2022 Dec 14.

 

Rozanne C de Veer 1, Maria C van Hooff 1, Christophe Corpechot 2, Douglas Thorburn 3, Pietro Invernizzi 4 5, Willem J Lammers 1, Harry L A Janssen 1 6, Pier M Battezzati 7, Frederik Nevens 8, Keith D Lindor 8 9 10, Annarosa Floreani 11 12, Cyriel Y Ponsioen 13, Marlyn J Mayo 14, Albert Parés 15, Andrew L Mason 16, Kris V Kowdley 17, Palak J Trivedi 18, Gideon M Hirschfield 6 18, Jorn C Goet 1, Tony Bruns 19 20, George N Dalekos 21 22, Nikolaos K Gatselis 21 22, Xavier Verhelst 23, Bettina E Hansen 1 6, Maren H Harms 1, Adriaan J van der Meer 1; Global PBC Study Group
 
11.Excellent outcome in patients with primary biliary cholangitis in Northwest Italy followed up for up to 30 years
 

Eur J Gastroenterol Hepatol. 2023 Aug 1;35(8):899-906.doi: 10.1097/MEG.0000000000002582. Epub 2023 Jun 6.

 

Cristina Rigamonti 1, Carla De Benedittis 1, Sara Labanca 2, Ester Vanni 3, Anna Morgando 3, Giulia Francesca Manfredi 1, Danila Azzolina 4, Micol Giulia Cittone 1, Edoardo Giovanni Giannini 2, Giorgio Maria Saracco 3, Mario Pirisi 1
 
12.Reliability of Medical Information Provided by ChatGPT: Assessment Against Clinical Guidelines and Patient Information Quality Instrument
 

J Med Internet Res. 2023 Jun 30;25:e47479. doi: 10.2196/47479.

 

Harriet Louise Walker 1, Shahi Ghani 1, Christoph Kuemmerli 2, Christian Andreas Nebiker 3, Beat Peter Müller 2, Dimitri Aristotle Raptis 4, Sebastian Manuel Staubli 1 2
 
13.The causal effects of inflammatory bowel disease on primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study
 

Liver Int. 2023 Aug;43(8):1741-1748. doi: 10.1111/liv.15616. Epub 2023 Jun 7.

 

Hongchen Zhang 1, Lanlan Chen 1, Zhongqi Fan 1, Guoyue Lv 1
 
14.GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus
 

Clin Gastroenterol Hepatol. 2023 Jul;21(7):1902-1912.e13.doi: 10.1016/j.cgh.2022.10.032. Epub 2022 Nov 4.

 

Cynthia Levy 1, Stuart Kendrick 2, Christopher L Bowlus 3, Atsushi Tanaka 4, David Jones 5, Andreas E Kremer 6, Marlyn J Mayo 7, Nazneen Haque 2, Robyn von Maltzahn 8, Matthew Allinder 9, Brandon Swift 10, Megan M McLaughlin 9, Gideon M Hirschfield 11; GLIMMER Study Group
 
15.Primary biliary cholangitis: primary autoimmune disease or primary secretory defect
 

Expert Rev Gastroenterol Hepatol. 2023 Jul 29. doi: 10.1080/17474124.2023.2242771.Online ahead of print.

 

Annarosa Floreani 1 2, Daniela Gabbia 3, Sara De Martin 3
 
16.Quality of life in Dutch patients with primary biliary cholangitis: Discrepancies between patients' perspectives and objective disease parameters
 

Hepatol Res. 2023 May;53(5):401-408. doi: 10.1111/hepr.13880. Epub 2023 Jan 24.

 

Rozanne C de Veer 1, Maria C van Hooff 1, Geraldine da Silva 1, Maren H Harms 1, Herold J Metselaar 1, José Willemse 2, Elaine Utomo 3, Adriaan J van der Meer 1
 
17.Primary biliary cholangitis: Epidemiology, prognosis, and treatment
 

Hepatol Commun. 2023 Jun 2;7(6):e0179. doi: 10.1097/HC9.0000000000000179.eCollection 2023 Jun 1.

 

Juan Trivella 1, Binu V John 2 3, Cynthia Levy 3
 
18.Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores
 

Hepat Med. 2023 Jun 8;15:63-77. doi: 10.2147/HMER.S361077. eCollection 2023.

 

Aalam Sohal 1, Kris V Kowdley 1 2
 
19.ACR Appropriateness Criteria® Right Upper Quadrant Pain: 2022 Update
 

J Am Coll Radiol. 2023 May;20(5S):S211-S223.doi: 10.1016/j.jacr.2023.02.011.

Expert Panel on Gastrointestinal Imaging; Gregory K Russo 1, Atif Zaheer 2, Ihab R Kamel 3, Kristin K Porter 4, Krystal Archer-Arroyo 5, Mustafa R Bashir 6, Brooks D Cash 7, Alice Fung 8, Marion McCrary 9, Brendan M McGuire 10, Richard D Shih 11, John Stowers 12, Kiran H Thakrar 13, Abhinav Vij 14, Shaun A Wahab 15, Katherine Zukotynski 16, Laura R Carucci 17
 
20.The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis
 

Hepatol Commun. 2023 Mar 24;7(4):e0068. doi: 10.1097/HC9.0000000000000068.eCollection 2023 Apr 1.

Lars Bossen 1, Tobias Stemann Lau 1, Mette Bak Nielsen 2, Marlene Christina Nielsen 3, Astrid Højmark Andersen 1, Peter Ott 1, Sabine Becker 4, Henning Glerup 4, Lise Svenningsen 5, Martin Eivindson 5, Linda Kornerup 1 6, Niels Bjørndal Kjeldsen 7, Anders Neumann 8, Holger Jon Møller 3, Peter Jepsen 1, Henning Grønbæk 1
 
21.Optimizing therapy in primary biliary cholangitis: Alkaline phosphatase at six months identifies one-year non-responders and predicts survival
 

Liver Int. 2023 May 8. doi: 10.1111/liv.15592. Online ahead of print.

C Fiorella Murillo Perez 1, Stephanie Ioannou 2, Iman Hassanally 3, Palak J Trivedi 4, Christophe Corpechot 5, Adriaan J van der Meer 6, Willem J Lammers 6, Pier Maria Battezzati 7, Keith D Lindor 8, Frederik Nevens 9, Kris V Kowdley 10, Tony Bruns 11, Nora Cazzagon 12, Annarosa Floreani 12 13, Andrew L Mason 14, Aliya Gulamhusein 1, Cyriel Y Ponsioen 15, Marco Carbone 16, Ana Lleo 17, Marlyn J Mayo 18, George N Dalekos 19, Nikolaos K Gatselis 19, Douglas Thorburn 20, Xavier Verhelst 21, Albert Parés 22, Maria-Carlota Londoño 22, Harry L A Janssen 1 6, Pietro Invernizzi 16, Raj Vuppalanchi 23, Gideon M Hirschfield 1, Bettina E Hansen 1 3 6, Cynthia Levy 2; Global PBC Study Group

 
 
22.Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial
 

Liver Int. 2023 May 15. doi: 10.1111/liv.15596. Online ahead of print.

Pietro Invernizzi 1 2, Marco Carbone 1 2, David Jones 3, Cynthia Levy 4, Nicola Little 5, Philippe Wiesel 6, Frederik Nevens 7; study investigators
 
23.Regulation of immune responses in primary biliary cholangitis: a transcriptomic analysis of peripheral immune cells
 

Hepatol Commun. 2023 Apr 4;7(4):e0110. doi: 10.1097/HC9.0000000000000110.eCollection 2023 Apr 1.

Victoria Mulcahy 1 2, Evaggelia Liaskou 3 4, Jose-Ezequiel Martin 1 5, Prasanti Kotagiri 6 7, Jonathan Badrock 1, Rebecca L Jones 8, Simon M Rushbrook 9, Stephen D Ryder 10, Douglas Thorburn 11, Simon D Taylor-Robinson 12, Graeme Clark 13, Heather J Cordell 14, Richard N Sandford 1, David E Jones 15 16, Gideon M Hirschfield 17, George F Mells 1 2
 
24.Efficacy and Safety of Bezafibrate Alone or in Combination with Ursodeoxycholic Acid in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis
 

Dig Dis Sci. 2023 Apr;68(4):1559-1573. doi: 10.1007/s10620-022-07704-4.Epub 2022 Sep 30.

Nidah Shabbir Khakoo 1, Shahnaz Sultan 2, John M Reynolds 3, Cynthia Levy 4 5
 
25.Role of autoantibodies in the clinical management of primary biliary cholangitis
 

World J Gastroenterol. 2023 Mar 28;29(12):1795-1810.doi: 10.3748/wjg.v29.i12.1795.

Eirini I Rigopoulou 1 2, Dimitrios P Bogdanos 3
 
View More
 
 
 

HEPATITIS

HBV
HCV
HDV

CLD HEALTH OUTCOMES

CIRRHOSIS

Cirrhosis
HE
HRS
Thrombocytopenia

NASH

Slide Library
Publications
Webcasts
Abstract Library Committee Members

CHOLESTATIC

PBC

HCC

Slide Library
Publications
Webcasts
Algorithm
Abstract Library Committee Members

ALCOHOL LIVER DISEASE

Recorded Educational Webinar

PEDIATRIC LIVER DISEASE

Webcasts
Slide Library
Abstract Library

About CLDF

Board of Trustees
Board of Advisors/Faculty
CLDF Committees
2023 GI Fellow Board of Advisors

Other Resources

Journal Abstracts

Subscribe

Be the first to know about our latest upcoming programs and events!
CLDF

Follow us
Facebook
Twitter
Youtube
LiverQ
The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2023 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.